<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491905</url>
  </required_header>
  <id_info>
    <org_study_id>12-HS-HP-09-1</org_study_id>
    <nct_id>NCT02491905</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients</brief_title>
  <official_title>Phase 2 Study to Assess Safety and Efficacy of HL Tablet on Reducing Hepatic Fat in Non-alcoholic Fatty Liver Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of HL tablet on reducing hepatic fat in&#xD;
      non-alcoholic fatty liver disease patients. The patients are allocated to three groups; low&#xD;
      dose, high dose, and placebo control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the change of hepatic fat by Magnetic Resonance spectroscopy (MRS) after administration of HL tablet compared with baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Alanine Transaminase (ALT)</measure>
    <time_frame>8 and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Asparate Transaminase (AST)</measure>
    <time_frame>8 and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cholesterol</measure>
    <time_frame>8 and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglyceride</measure>
    <time_frame>8 and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in free fatty acid</measure>
    <time_frame>8 and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin resistance</measure>
    <time_frame>8 and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Mass Index (BMI)</measure>
    <time_frame>8 and 12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>low dose HL tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL tablet which contains 66.7mg of active compound by oral administration, twice daily in an hour after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose HL tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL tablet which contains 200mg of active compound by oral administration, twice daily in an hour after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by oral administration, twice daily in an hour after meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL tablet</intervention_name>
    <arm_group_label>high dose HL tablet</arm_group_label>
    <arm_group_label>low dose HL tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 19 and 75&#xD;
&#xD;
          2. Non-alcoholic fatty liver disease patient&#xD;
&#xD;
               -  Diagnosed by abdomen ultrasonic examination&#xD;
&#xD;
               -  Non-drinker (alcohol intake per week : female-under 140g, male-under 210g)&#xD;
&#xD;
          3. ALT or AST higher than normal range (not over 4 times normal range)&#xD;
&#xD;
          4. Voluntary agreement and enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The ratio of AST/ALT over 2&#xD;
&#xD;
          2. Type I diabetes mellitus patient&#xD;
&#xD;
          3. Any dysfunction of liver besides non-alcoholic fatty liver disease&#xD;
&#xD;
          4. Alcoholic fatty liver disease patient or heavy drinker&#xD;
&#xD;
          5. Prior treatment with any medicine which affects the treatment of non-alcoholic fatty&#xD;
             liver disease within 3 months&#xD;
&#xD;
          6. Patient taking any product which affects the BMI or hyperlipidemia&#xD;
&#xD;
          7. Any dyscrasia that investigator considers not to appropriate for this study&#xD;
&#xD;
          8. Bariatric surgery within 6 months&#xD;
&#xD;
          9. Any disease which is able to change the distribution of cytokines&#xD;
&#xD;
         10. Any treatment that affects liver functions within 1 month&#xD;
&#xD;
         11. Participation in other clinical trials within 3 months&#xD;
&#xD;
         12. Person who can not use MRS&#xD;
&#xD;
         13. Pregnancy or breast-feeding&#xD;
&#xD;
         14. Fertile women who do not use contraception&#xD;
&#xD;
         15. Sensitive to the investigational product&#xD;
&#xD;
         16. Any conditions that the investigator considers not to appropriate for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huons</name>
      <address>
        <city>Ansan</city>
        <state>Kyeonggi-do</state>
        <zip>426791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

